1. Pharmacologic Management of End-of-Life Delirium: Translating Evidence into Practice.
- Author
-
Hui, David, Cheng, Shao-Yi, and Paiva, Carlos Eduardo
- Subjects
- *
BENZODIAZEPINES , *ATTITUDES toward death , *PALLIATIVE treatment , *PSYCHOMOTOR disorders , *PSYCHOLOGICAL distress , *DEATH , *CRITICALLY ill , *PATIENTS , *ANTIPSYCHOTIC agents , *TRANQUILIZING drugs , *DELIRIUM , *TUMORS , *EVIDENCE-based medicine , *DISEASE complications - Abstract
Simple Summary: In the last days and weeks of life, many patients with cancer develop delirium with fluctuating confusion, altered levels of consciousness, hallucinations, restlessness, and, sometimes, agitation, which fluctuate over time. This condition can be very distressing for the patient and their family. In this article, the authors reviewed different treatments for delirium in patients receiving palliative care. Previous studies have shown that certain medications, such as neuroleptics and benzodiazepines, may be helpful in controlling the terminal agitation associated with end-of-life delirium. However, further research is needed to confirm these findings and find new treatment options to address this challenging issue. End-of-life delirium affects a vast majority of patients before death. It is highly distressing and often associated with restlessness or agitation. Unlike delirium in other settings, it is considered irreversible, and non-pharmacologic measures may be less feasible. The objective of this review is to provide an in-depth discussion of the clinical trials on delirium in the palliative care setting, with a particular focus on studies investigating pharmacologic interventions for end-of-life delirium. To date, only six randomized trials have examined pharmacologic options in palliative care populations, and only two have focused on end-of-life delirium. These studies suggest that neuroleptics and benzodiazepines may be beneficial for the control of the terminal restlessness or agitation associated with end-of-life delirium. However, existing studies have significant methodologic limitations. Further studies are needed to confirm these findings and examine novel therapeutic options to manage this distressing syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF